[P02] Poster 2 (5. Vaccine / Even Number)

[P114] Immune resilience to cancer by repurposing unique Mycobacterium tuberculosis-specific CD4 memory T cells

○Burcu Temizoz^1,2,6,7,8, Nobuyoshi Kobayashi^2,3,8, Yuta Ohira^2,3,8, Areej Sakkour¹, Kou Hioki¹, Mai Onaga¹, Tomoya Hayashi^1,2,6,7, Michelle Sue Jann Lee^5,6, Takayuki Horii³, Cevayir Coban^4,5,6,7, Kouji Kobiyama^1,2,6,7, Ken J Ishii^1,2,4,6,7 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan (Japan), 2. Center for Adjuvant and Vaccine Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8, Osaka, Japan (Japan), 3. Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1 Numagami, Oshikiri, Kumagaya-shi, Saitama, Japan (Japan), 4. WPI Immunology Frontier Research Center (IFReC), Osaka University, 3-3-1, Osaka, Japan (Japan), 5. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, 4-6-1, Tokyo, Japan (Japan), 6. International Vaccine Design Center (VDesC), The Institute of Medical Science (IMSUT), The University of Tokyo, 4-6-1, Tokyo, Japan (Japan), 7. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo 108-8639, Japan. (Japan), 8. These authors contributed equally. (Japan))

Password required to view